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SUMMARY – Multifocal motor neuropathy (MMN) is a chronic demyelinating neuropathy 
mainly characterized by multifocal distribution; aff ecting only motor nerve fi bers of two or more pe-
ripheral nerves, with the absence of symptoms and signs of upper motor neuron; chronic, sometimes 
cascading progressive course; demyelination with partial block of motor conduction; immune-medi-
ated pathogenesis and good response to intravenous immunoglobulin treatment (IVIG). Th e diagno-
sis of MMN is based on clinical, laboratory and electrophysiological characteristics. Steroids are inef-
fective in MMN and may lead to worsening of the disease. Similarly, therapeutic plasma exchange is 
negligibly eff ective in this neuropathy. However, more than 80% of patients with MMN experience 
improvement after IVIG. We present our three cases of MMN with positive response to IVIG.
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Introduction
Multifocal motor neuropathy (MMN) is an ac-
quired, chronic, immune-mediated demyelinating neu-
ropathy. Parry and Clark were the fi rst to describe the 
disease discovered in fi ve diff erent patients in 1982 as 
a chronic, demyelinating, and sensorimotor multiple 
mononeuropathy. Later, in 1988, Pestronk and associ-
ates introduced the term “multifocal motor neuropa-
thy” and they discovered the MMN connection with 
anti-GM1 IgM antibodies and positive response to 
immunomodulatory therapy. Since then, clinical and 
electrophysiological evaluation of large cohorts of pa-
tients have increased our understanding of the patho-
physiology of MMN and paved the way for more ef-
fective treatment1-4.
Th e main clinical feature of MMN is slow progres-
sive or cascading, asymmetric, predominantly distal 
extremity weakness without objective loss of sensation 
in the distribution of two or more peripheral nerves 
without signs of upper motor neuron lesion1,3. MMN 
is a rare disease with a frequency of 1-2/100 000. It is 
more common in men than in women at a ratio of 
about 3:1. About 80% of people experience the fi rst 
symptoms between the ages of two and fi ve decades of 
life. Th e average age at onset is 40 years1. MMN main-
ly aff ects younger people. Upper extremities are usually 
aff ected more often and more seriously than the lower 
ones4. Proximal weakness is manifested in only 5%-
10% of MMN cases. Th e most common initial symp-
tom is weakness of the wrist (wrist drop), as well as 
weakness of the hand grip. Muscle weakness is usually 
mild but can progress and it is usually associated with 
poor response to therapy. Other symptoms that may 
occur are fasciculations and muscle picks noted in 
about 50% of cases. Th e main characteristic of MMN 
is the lack of sensory symptoms. Only a few patients 
complain of discrete paresthesia or a feeling of numb-
ness in the limbs. In about 20% of cases, there is minor 
disturbance of vibratory sensitivity. Tendon refl exes of 
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weakened muscles are usually reduced but may be nor-
mal or rarely even lively. Cranial nerve involvement is 
uncommon and, if present, it predominantly aff ects 
hypoglossal nerve.
Diagnosis is based on history data, clinical picture 
and electromyoneurography (EMNG) as the gold 
standard. A marker is multifocal conduction block 
(CB) on EMNG testing1,2,4,5. Conduction block is re-
duction in the amplitude and area of compound mus-
cle action potential (CMAP) obtained from the proxi-
mal point of stimulation compared to the CMAP ob-
tained from the distal point of peripheral nerve. Gen-
erally, CB will appear when an incoming action 
potential at the level of Ranvier’s node is unable to 
induce suffi  cient depolarization in the next sub-seg-
ments that would generate further action potential. 
Th e basis of CB formation is focal demyelination ex-
perimentally demonstrated in rodents. Apart from de-
myelination, axonal lesions may occur as well. Studies 
have indicated a functional role in the disintegration of 
the axonal impairment of the axon-myelin interaction.
In addition to CB, EMNG testing can indicate the 
speed of conduction deceleration, prolongation of dis-
tal latency and F-responses as well.
To be diagnosed with MMN, CB must be estab-
lished in at least two peripheral nerves1,4,5. Laboratory 
tests show a high titer of IgM anti-GM1 ganglioside 
antibodies that are recorded in 30%-80% of patients; 
however, negative fi nding does not exclude MMN1. 
Slightly elevated levels of creatine kinase can be found 
in two-thirds of patients. Cerebrospinal fl uid in MMN 
usually is of normal composition, or occasionally may 
exhibit slight increase in protein concentration (up to 
80 mg/dL) and the reference number of cells.
Magnetic resonance imaging (MRI) in 50% of 
cases may demonstrate enhancement of the T2 signal 
intensity in a part of the brachial plexus (if upper ex-
tremity is aff ected). In the future, MRI can become an 
elegant and noninvasive tool for assessing the integrity 
of the proximal nerve segments, bearing in mind that 
abnormal fi ndings on MRI are usually asymmetric and 
the technique can help in diff erentiating MMN from 
chronic infl ammatory demyelinating polyneuropathy, 
which is characterized by abnormal MRI fi nding that 
is mostly symmetric, as well as from the lower motor 
neuron diseases, where MRI fi ndings are normal1,4. 
Nerve biopsy is rarely necessary to distinguish between 
MMN and nerve tumor or vasculitis. A biopsy can 
show nerve demyelination, bulb formation and axonal 
atrophy4.
Th e treatment of choice is intravenous administra-
tion of immunoglobulin (IVIG) in a dose of 0.4 g/kg/
day for two to fi ve days1,4,6,7. After an initial therapeutic 
eff ect, depending on the clinical picture dynamics, it is 
recommended to repeat the same dose of 0.2 g/kg/day 
in 15-30 days or the originally specifi ed dose every one 
to two months. Th e clinical eff ect of IVIG is impres-
sive and muscle power is usually quickly repaired in 
the fi rst week after administration of the fi rst dose. 
However, the eff ect of therapy is partly reduced after a 
few weeks. Th e eff ectiveness of IVIG decreases natu-
rally with age, and higher doses or shorter intervals 
between doses are usually needed. Recently, tests of ef-
fectiveness of applications of higher initial doses of 
IVIG to prevent secondary degeneration of axons and 
increased remyelination are being carried out and they 
are yet to be explained in larger studies in the period to 
come.
Subcutaneous IG application is advantageous for 
providing steadier plasma concentration of IG and 
thus better quality of life, while the economic aspect 
would not be negligible as well. Th is possibility should 
be additionally analyzed in the future.
In MMN cases when IVIG is not eff ective, cyclo-
phosphamide is the next recommendation4. Cyclo-
phosphamide has so far been tested in several small, 
uncontrolled studies. It was concluded that high doses 
of cyclophosphamide had a moderate eff ect, especially 
when administered intravenously, whereas oral admin-
istration showed no signifi cant eff ect on the progres-
sion of the disease. However, cyclophosphamide is not 
recommended as a treatment by one group of experts 
because there is an opinion of the short-term and 
long-term toxicity and lack of evidence for effi  ciency 
in MMN4. We present our three cases of MMN.
Case Reports
Case 1
M.M., a 14-year-old boy, had a feeling of weakness 
in the left foot, which lasted for about two months. 
Neurologic examination revealed inability of dorsifl ex-
ion of the left foot with hypotrophy of m. extensor digi-
torum brevis (MEDB). Plantar fl exion was possible, as 
well as supporting on the left toes. Patellar refl exes 
were symmetrically vivid. Left Achilles refl ex was re-
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duced. Sensitivity was neat. He could not stand up 
from squat on full feet. He walked with left peroneal 
weakness.
Electromyoneurography testing revealed a milder 
loss of motor neurons in the analyzed m. abductor di-
giti minimi analyzed on the right hand, with normal 
fi ndings in other muscles of the right hand. Th e mus-
cles of his left leg showed a signifi cant loss of moto-
neurons in all muscles analyzed, up to denervation in 
the left MEDB. EMNG fi ndings in the muscle of the 
right leg were completely normal. Motor conduction 
velocity (MCV) on plurisegmental analysis, through 
all segments of the right ulnar nerve was normal, as 
well as through both deep peroneal and left femoral 
nerve. MCV through the sciatic nerve in the segment 
before the fork was slightly reduced, but was normal 
through tibial nerve. Th is nerve showed a possibility of 
partial CB (Fig. 1).
After the initial immunoglobulin i.v. application at 
a dose of 0.4 g/kg body weight per day for fi ve con-
secutive days, minimal improvement of neurologic 
defi cit was observed. Weakness of the left leg was still 
present, but it was reduced. Plantar fl exion showed 
much better power compared to the previous fi nding. 
Minimal activation of the foot extensor was possible. 
After physical treatment and administration of the 
second dose of immunoglobulin, additional improve-
ment of neurologic defi cit was evident. Plantar fl exion 
of the left foot was possible to middle position, while 
walking was still clearly peroneal. After the third dose 
of IVIG, walking was practically normal. He could 
squat relatively correctly, standing up without diffi  cul-
ty but could not squat on full feet. Left Achilles ten-
don was shortened. Active dorsifl exion of the left foot 
and against resistance, as well as dorsifl exion and plan-
tar fl exion of the toes was almost normal. Left MEDB 
was less voluminous and slightly smaller than the right 
one. Patellar refl exes were symmetric and appropriate. 
Achilles refl exes were symmetric and appropriate.
Follow up EMNG performed one month after the 
third dose of IVIG indicated partial CB. MCV of the 
left ischiadic nerve (tibial nerve) was normal in the 
segment through tibial nerve and slightly reduced in 
the proximal segment over the crossroads on the ter-
minal branches, and partial CB was recorded when the 
nerve was stimulated at its most proximal point.
Case 2
B.A., a 19-year-old boy, felt weakness in his left 
foot. Six months before, while playing football, he 
raised his left leg and then felt weakness and clumsi-
ness in the left foot. He did not pay much attention to 
this event. Two months later, his parents noticed his 
problem. Th ey noticed that he could not raise the left 
toe. He denied feeling pain in his left leg or back pain 
or any other symptoms.
Fig. 1. Left sciatic nerve (n. tibialis), plurisegmental analysis of motor conduction 
velocity (partial conduction block).
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Neurologic examination revealed peroneal walk on 
the left leg. He could walk on his toes. Dorsifl exion of 
the left foot was limited. He could squat without prob-
lems but could not crouch on full feet; he rather sup-
ported on his toes. Th ere was noticeable weakness of 
the tibial muscle of the left leg, with a clear front edge 
of the tibia. Patellar refl ex was reduced on the left. 
Achilles tendon refl exes were symmetric and appropri-
ate. Th e toes of the left foot except for the thumb were 
in spontaneous dorsifl exion with deformities in terms 
of dorsifl exion of the proximal phalanx and plantar 
fl exion of the distal phalanx. Th e arches of both feet 
were raised, higher on the left foot. Left MEDB was 
atrophic. Th ere was no sensitivity disturbance.
Electromyoneurography testing showed overt loss 
of motor neurons in all muscles of his left leg. Milder 
loss of motor neurons was evident in the area of the 
right foot. Neurography showed normal MCV in the 
left nerves analyzed (deep peroneal nerve, tibial nerve, 
femoral nerve).
Follow up examination was performed after treat-
ment with IVIG in a dose of 0.4 g/kg body weight for 
fi ve days and another IVIG treatment later at a dose of 
0.2 g/kg for fi ve days. Th ere was an occasional feeling 
of stiff ness in the back of the left knee. Th e patient also 
noted some weakness in his left leg but no problems in 
his hands or right leg. Occasionally, the patient ob-
served twitching muscles in his left thigh. Neurologic 
examination revealed precise walking on the toes, a 
little harder on the heel of the left foot. Hypotrophy of 
the muscle in his left lower leg was noticeable. Th e pa-
tient could squat on full feet and rise from the squat 
without diffi  culty. Th e patient could raise outstretched 
left foot from the ground lying on his back with resis-
tance (grade 4/5). Th e upper left leg exhibited a possi-
ble myokymia. Left patellar refl ex could not be pro-
voked. Achilles tendon refl exes were normal. Left 
MEDB was less voluminous than the right one. 
Babinski sign was negative.
Follow up EMNG testing showed normal motor 
conduction velocity in the analyzed segment of the 
right ulnar nerve, partial CB in the analysis of the left 
deep peroneal nerve and left tibial nerve in proximal 
segments (distal part of ischiadic nerve), with milder 
deceleration of motor conduction velocity in all seg-
ments (Fig. 2).
Case 3
I. H., a 26-year-old man, had occasionally felt 
short-term numbness in the left leg in the past 15 
days. Th e day before admission to the hospital, he felt 
numbness in his left leg again that lasted for about fi ve 
minutes and then he felt weakness in his left foot. 
Since then, there was no feeling of numbness. He 
thought that there was some recovery of weakness in 
his left foot. Two years before, he had sustained a traf-
fi c accident as a pedestrian, and then he got a kick in 
the left leg. Th ere were no fractures but his left leg was 
Fig. 2. Left deep peroneal nerve (partial conduction block).
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swollen for a while. He had previously practiced sports 
(football).
Neurologic testing showed walking that was dis-
cretely peroneal on the left. He could walk on his toes, 
with shortness of the left heel. He could not stand up 
from full squat on the feet (noting that he could not 
have done that before either). Achilles tendon was 
shortened bilaterally. Intraosseous drawing on both 
feet was emphasized. Minimal dorsifl exion was possi-
ble in the left foot, but not to 90 degrees as far as he 
could be passive. Toes were practically without dorsi-
fl exion. Plantar fl exion of the toes and both feet was 
normal. Left MEDB was atrophic. Patellar refl exes 
were normal. Th ere were no disturbances of sensitivity. 
Babinski sign was negative.
Electromyoneurography testing revealed clear loss 
of motor neurons in the analyzed muscle of his left leg, 
predominantly distal, most pronounced in MEDB. 
Neurography analysis pointed to CB in the analyzed 
left deep peroneal nerve, with slight reduction in the 
motor conduction velocity (Fig. 3) and normal neuro-
graphs for the left tibial nerve.
One month after the administration of IVIG in a 
dose of 0.4 g/kg body weight for fi ve days, he felt bet-
ter. His left foot was stronger and more mobile. Neu-
rologic testing revealed walking on heels and walking 
on his toes was normal. He could squat without diffi  -
culty, but he could not do full feet squat without sup-
port. Patellar refl exes were normal. Achilles refl exes 
were normal. Left MEDB was ‘wiped out’. Th ere were 
no disturbances of sensitivity. EMNG showed normal 
motor conduction through the left deep peroneal 
nerve and left tibial nerve without CB.
Discussion
Multifocal motor neuropathy is not as rare clinical 
entity in practice and should be diagnosed as soon as 
possible. Th e patient M.M. gave unreliable informa-
tion on the onset of symptoms. Probably a month and 
a half to two months had elapsed from the onset of 
symptoms to the diagnosis and IVIG administration, 
while the patient B.A. was examined about six months 
after the onset of symptoms. It is likely that therapeu-
tic response would have been better had it been ap-
plied  earlier.
On routine EMNG, one should be careful because 
the CB can ‘hide’ in the proximal or distal parts of the 
nerves tested4. In some patients with MMN and clear 
clinical picture, CB cannot be proven, probably be-
cause it is present in the nerves or part of the nerve 
that cannot be EMNG analyzed at the given moment 
or when CB is present in the proximal or distal part of 
the nerve that has not been tested in routine EMNG. 
In such cases, it is recommended to use transcortical 
magnetic stimulation of spinal roots for detection of 
CB in the proximal segment of the nerve. In case of 
the patient M.M., standard EMNG analysis was ex-
Fig. 3. Left deep peroneal nerve (conduction block).
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tended and the left partial CB was recorded in ischi-
adic nerve (tibial nerve) in the segment before the fork, 
whereas in the patient I.H. clear CB of the left deep 
peroneal nerve was detected.
In MMN, there is slow progressive or cascading 
progressive, focal, asymmetric muscle weakness in the 
area of innervation of at least two peripheral nerves for 
at least a month. In Case 1, the symptoms lasted for 
more than a month, with very possible mild slow pro-
gression.
If the symptoms and signs are present only in the 
distribution of one of the peripheral nerves, diagnosis 
of a possible MMN can be made, which was done in 
M.M. at the fi rst clinical and EMNG examination. In 
early stages, the degree of muscle weakness is equal to 
the degree of muscle atrophy. Th is phenomenon indi-
cates a primary demyelination disorder rather than 
axonal lesion. It is interesting that a large number of 
studies on nerve conduction showed improvement in 
conductivity after the application of IVIG, although 
recovery of muscle strength is rarely complete in these 
patients.
In M.M., there was improvement of MCV in the 
ischiadic nerve (tibial nerve), as well as improvement 
of the strength and mobility in the left foot. In case 2, 
slight but not complete improvement was recorded af-
ter treatment. In I. H., EMNG analysis after IVIG 
was practically normal and indicated clinical recovery. 
Th e curiosity with I.H. was that clear CB was found 
only in this patient.
Multifocal motor neuropathy must be distin-
guished from Lewis-Sumner syndrome (LS) and the 
primary diff erence is the absence of sensory symptoms 
in MMN, whereas LS shows signifi cant presence of 
sensory symptoms, often associated with neuropathic 
pain. Th erefore, neurographic detection of a reduced 
potential in a variety of sensory nerves is the most re-
alistic criterion to diff erentiate LS from MMN. Th e 
patient M.M. felt slight numbness in the left foot at 
the beginning of the appearance of symptoms, whereas 
I.H. stated that he had occasionally felt short-term 
numbness in the left leg for 15 days prior to admission 
in the hospital. Th e day before admission to the hospi-
tal, he felt numbness again in his left leg for about fi ve 
minutes, with the appearance of weakness in the left 
foot.
Lewis-Sumner syndrome is characterized by the 
absence of anti-GM1 antibodies, and proteins in the 
cerebrospinal fl uid are often increased. In MMN, there 
may be a minor sensory defi cit in terms of mild palles-
thesia in the legs4. Unlike LS, patients with MMN 
have no positive response to the treatment with corti-
costeroids and plasmapheresis. Studies have recorded 
better treatment response in younger patients. In a 
number of uncontrolled studies, some patients showed 
positive therapeutic response to treatment with cyclo-
phosphamide, interferon beta-1a, cyclosporine, meth-
otrexate and azathioprine2,4,5,8.
Some studies suggest that the frequency of other 
autoimmune diseases is higher in patients with MMN 
(more pronounced in women) and in close family 
members of patients than in control group. It has been 
observed that there is a higher frequency of HLA-
DRB1* 15 in these patients and that the characteris-
tics of the disease are associated with particular HLA 
types9.
Conclusion
Multifocal motor neuropathy is a rare and dis-
abling disease. In patients with MMN, muscle weak-
ness is the consequence of CB, which leads to second-
ary axonal degeneration. Consequently, the aim of the 
treatment is to reverse CB at early stages of the dis-
ease. High-dose immunoglobulin is for now the only 
therapy with proven effi  ciency in MMN patients by 
providing transient improvement of muscle strength, 
but long-term follow up studies show a progressive 
motor decline. We presented our three cases of MMN 
with positive response to IVIG. Diagnosis was based 
on EMNG tests, clinical features and positive response 
to treatment with immunoglobulins. According to the 
European Federation of Neurological Societies guide-
lines, MMN is a clearly defi ned clinical entity and it 
should be diagnosed on time and treated with IVIG. 
In addition to the application of immunoglobulin, an 
additional therapeutic option is continuous physical 
therapy.
References
1. Nguyen TP, Chaudhry V. Multifocal motor neuropathy. Neurol 
India. 2011;59(5):700-6. doi: 10.1186/1752-0509-5-179.
2. Meuth SG, Kleinschnitz C. Multifocal motor neuropathy: up-
date on clinical characteristics, pathophysiology concepts and 
E. Jusufović et al. Multifocal motor neuropathy
Acta Clin Croat, Vol. 57, No. 3, 2018 587
therapeutic options. Eur Neurol. 2010;63(4):193-204. doi: 
10.159/000282734.
3. Sinanović O. Imunološki posredovane neuromišićne bolesti. 
Neurol Croat. 2010;59(Suppl 1):61-72. (in Croatian)
4. Schulte-Mattler WJ, Müller T, Georgiadis D, Kornhuber ME, 
Zierz S. Length dependence of variables associated with tem-
poral dispersion in human motor nerves. Muscle Nerve. 2001;
24:527-33.
5. Garg N, Park SB, Vucic S, Yiannikas C, Spies J, Howells J, 
Huynh W, Matamala MJ, Krishnan VA, Pollard DJ, Cornblath 
RD, Reilly MM, Kierman CM. Diff erentiating lower motor 
neuron syndromes. J Neurol Neurosurg Psychiatry. 2017;88:
474-83. doi: 10.136/jmp-2016-313526.
6. Koski CL. Treatment of multifocal motor neuropathy with in-
travenous immunoglobulin. J Clin Immunol. 2014;Suppl 1:
S127-S131. doi: 10.1007/s10875-014-0016-5.
7. Stangel M, Gold R, Pittrow D, Baumann U, Borte M, Fass-
hauer M, Hensel M, Huscher D, Reiser M, Sommer C. Treat-
ment of patients with multifocal motor neuropathy with im-
munoglobulins in clinical practice: the SIGNS registry. Th er 
Adv Neurol Disord. 2016;9(3):165-79. 
 doi: 10.1177/1756285616629869.
8. van Schalk N, Bouche P, Illa I, Leger JM, Van den Berg P, 
Cornblath DR, Evers E, Hadden RDM, Hughes RAC, Koski 
CL, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA. 
Multifocal motor neuropathy. In: Hughes R, Brainin M,  Gilhus 
NE (eds). European Handbook of Neurological Management. 
Oxford: Blackwell Publishing, 2006; p. 354-61.
9. Sutedja NA, Otten HG, Cats EA, Piepers S, Veldnik JH, 
van der Pol WL, van den Berg LH. Increased frequency of 




MULTIFOKALNA MOTORNA NEUROPATIJA: PRIKAZI SLUČAJA
E. Jusufović, O. Sinanović, S. Zukić, A. Burina, Z. Džinić Jusufović i A. Šakić
Multifokalna motorna neuropatija (MMN) je kronična demijelinizirajuća neuropatija koja je obilježena multifokalnom 
distribucijom; zahvaćanjem samo motornih živčanih vlakana dvaju ili više perifernih živaca, uz odsutnost znakova lezije 
gornjega motornog neurona; kroničnim, ponekad kaskadnim progresivnim tijekom; demijelinizacijom s djelomičnim  blokom 
motornog provođenja; imunosno posredovanom patogenezom i dobrim odgovorom na terapiju intravenskim imunoglobu-
linom (IVIG). Dijagnoza se postavlja na osnovi kliničke slike, laboratorijskih i elektrofi zioloških parametara. Steroidi su 
neučinkoviti kod MMN, a mogu dovesti i do pogoršanja bolesti. Slično, terapijska izmjena plazme je zanemarivo učinkovita 
u ovoj neuropatiji. Međutim, više od 80% bolesnika s MMN imaju poboljšanje nakon IVIG. U radu prikazujemo naša tri 
slučaja MMN s pozitivnim odogovorom na IVIG.
Ključne riječi: Polineuropatije; Demijelinizacijske bolesti; Periferni živci; Motorički neuroni; Imunoglobulini, intravenski
